WHO ICTRP trial
Tamoxifen Citrate in Treating Premenopausal Women With Estrogen…
NCT01658566 · NIH Clinical Trials · Recruiting
Key facts
| Trial ID | NCT01658566 |
|---|---|
| Public title | Tamoxifen Citrate in Treating Premenopausal Women With Estrogen Receptor-Positive Breast Cancer |
| Scientific title | Pilot Study to Analyze a Novel Mechanism Underlying Response to Tamoxifen Therapy in Breast Cancer Patients |
| Primary sponsor | Roswell Park Cancer Institute |
| Secondary sponsors | National Cancer Institute (NCI) |
| Registry | NIH Clinical Trials |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Countries | United States |
| Conditions | Estrogen Receptor-positive Breast Cancer;Stage I Breast Cancer;Stage II Breast Cancer;Stage IIIA Breast Cancer;Stage IIIB Breast Cancer;Stage IIIC Breast Cancer;Stage IV Breast Cancer |
| Interventions | Drug: tamoxifen citrate;Genetic: polymerase chain reaction;Other: pharmacological study;Genetic: gene expression analysis;Other: immunohistochemistry staining method;Other: pharmacogenomic studies;Other: matrix-assisted laser… |
| Registration date | Jul 23, 2012 |
| Target size | 50 |
| Secondary IDs | NCI-2009-01760;R21CA137635;I 110907 |
| Registry page | clinicaltrials.gov |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: